repaglinide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antihyperglycaemics 2366 135062-02-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • repaglinide
  • (S)-(+)-Repaglinide
  • prandin
  • enyglid
  • surepost
  • Molecular weight: 452.60
  • Formula: C27H36N2O4
  • CLOGP: 5.66
  • LIPINSKI: 1
  • HAC: 6
  • HDO: 2
  • TPSA: 78.87
  • ALOGS: -5.19
  • ROTB: 10
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
4 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine) 1.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.47 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 56 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.35 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 7.80 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.02 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.87 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 0.04 mg/mL Bocci G, Oprea TI, Benet LZ

Approvals:

DateAgencyCompanyOrphan
Dec. 22, 1997 FDA NOVO NORDISK INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypoglycaemia 665.61 17.19 270 9077 59795 63419880
Lactic acidosis 365.53 17.19 155 9192 38132 63441543
Acute kidney injury 319.47 17.19 282 9065 263133 63216542
Hypoglycaemic coma 180.04 17.19 47 9300 2528 63477147
Drug interaction 120.54 17.19 158 9189 228973 63250702
Hyperkalaemia 119.66 17.19 83 9264 54120 63425555
Diabetes mellitus inadequate control 80.74 17.19 41 9306 15085 63464590
Pemphigoid 77.54 17.19 32 9315 7312 63472363
Blood glucose increased 69.35 17.19 73 9274 83683 63395992
Sopor 66.11 17.19 41 9306 22123 63457552
Hyperglycaemia 58.85 17.19 49 9298 41818 63437857
Metabolic acidosis 55.70 17.19 49 9298 45020 63434655
Transcription medication error 53.05 17.19 11 9336 211 63479464
Pancreatitis acute 49.37 17.19 37 9310 27129 63452546
Prothrombin consumption time prolonged 48.78 17.19 8 9339 37 63479638
Anuria 47.29 17.19 27 9320 12524 63467151
Hepatocellular injury 46.91 17.19 36 9311 27345 63452330
Product prescribing error 43.80 17.19 34 9313 26255 63453420
Rhabdomyolysis 41.23 17.19 41 9306 43910 63435765
Drug ineffective 40.74 17.19 57 9290 1044708 62434967
Diabetic ketoacidosis 37.42 17.19 28 9319 20477 63459198
Anaemia 35.31 17.19 109 9238 293321 63186354
Dehydration 34.81 17.19 78 9269 173276 63306399
Rash maculo-papular 34.15 17.19 32 9315 31864 63447811
Confusional state 33.40 17.19 93 9254 236287 63243388
Renal failure 28.30 17.19 57 9290 117595 63362080
Poverty of speech 27.89 17.19 7 9340 321 63479354
Ischaemic stroke 27.28 17.19 22 9325 17935 63461740
Pain 27.21 17.19 42 9305 740586 62739089
Cholestasis 26.76 17.19 27 9320 29407 63450268
Septic shock 26.08 17.19 40 9307 66589 63413086
Medication error 25.74 17.19 35 9312 52249 63427426
Euglycaemic diabetic ketoacidosis 25.74 17.19 12 9335 3662 63476013
Resting tremor 25.65 17.19 8 9339 815 63478860
Asthenia 24.89 17.19 117 9230 383487 63096188
Arthropathy 24.29 17.19 3 9344 234789 63244886
Somnambulism 23.81 17.19 13 9334 5530 63474145
Drug reaction with eosinophilia and systemic symptoms 23.64 17.19 27 9320 33809 63445866
Hypokalaemia 23.43 17.19 49 9298 103755 63375920
Hypoglycaemic encephalopathy 23.28 17.19 6 9341 306 63479369
Arthralgia 23.19 17.19 30 9317 569680 62909995
Autoimmune haemolytic anaemia 23.18 17.19 12 9335 4589 63475086
Subacute cutaneous lupus erythematosus 22.86 17.19 10 9337 2633 63477042
Maternal exposure during pregnancy 22.31 17.19 3 9344 220059 63259616
Peripheral swelling 21.96 17.19 6 9341 265936 63213739
Abdominal discomfort 21.79 17.19 10 9337 320875 63158800
Fall 21.44 17.19 114 9233 392220 63087455
Pancreatitis 21.42 17.19 31 9316 49024 63430651
Vascular purpura 21.06 17.19 8 9339 1470 63478205
Dermatitis bullous 21.06 17.19 14 9333 8494 63471181
Cerebral haemorrhage 20.59 17.19 24 9323 30705 63448970
Disorientation 20.32 17.19 27 9320 39425 63440250
Renal impairment 20.28 17.19 42 9305 88313 63391362
Hepatitis fulminant 20.28 17.19 10 9337 3454 63476221
Infusion related reaction 19.42 17.19 6 9341 245515 63234160
Hypotension 19.03 17.19 85 9262 272519 63207156
Therapeutic product effect decreased 18.73 17.19 3 9344 193184 63286491
Rheumatoid arthritis 18.69 17.19 7 9340 253812 63225863
Joint swelling 18.26 17.19 13 9334 327653 63152022
Gingival abscess 17.32 17.19 6 9341 848 63478827

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypoglycaemia 689.28 15.46 340 10911 54300 34891380
Lactic acidosis 283.14 15.46 162 11089 34610 34911070
Hypoglycaemic coma 175.56 15.46 54 11197 2377 34943303
Acute kidney injury 167.02 15.46 327 10924 304661 34641019
Drug interaction 111.01 15.46 232 11019 225714 34719966
Pemphigoid 56.37 15.46 35 11216 8631 34937049
Diabetes mellitus inadequate control 53.29 15.46 40 11211 13424 34932256
Hyperkalaemia 52.47 15.46 86 11165 69303 34876377
Sopor 50.15 15.46 37 11214 12099 34933581
Oesophageal perforation 47.75 15.46 17 11234 1182 34944498
Hyperglycaemia 44.39 15.46 59 11192 39421 34906259
Cardiac failure 43.75 15.46 93 11158 91155 34854525
Cholestasis 41.16 15.46 47 11204 26901 34918779
Erythromelalgia 40.64 15.46 8 11243 49 34945631
Polymerase chain reaction 35.93 15.46 8 11243 95 34945585
Bradyphrenia 35.37 15.46 21 11230 4777 34940903
Coronavirus infection 34.79 15.46 20 11231 4287 34941393
Acute coronary syndrome 34.20 15.46 31 11220 13514 34932166
Hepatocellular injury 32.68 15.46 38 11213 22173 34923507
Renal failure 31.53 15.46 103 11148 130454 34815226
Eosinophilia 30.72 15.46 40 11211 26182 34919498
Anuria 30.70 15.46 26 11225 10359 34935321
Hyperkinetic heart syndrome 28.99 15.46 7 11244 121 34945559
Pericardial haemorrhage 26.40 15.46 15 11236 3143 34942537
Product prescribing issue 25.67 15.46 13 11238 2166 34943514
Drug ineffective 24.59 15.46 71 11180 456680 34489000
Urine leukocyte esterase positive 23.88 15.46 8 11243 463 34945217
Loss of consciousness 23.44 15.46 69 11182 82598 34863082
Hypoglycaemic encephalopathy 23.11 15.46 7 11244 292 34945388
Glycosylated haemoglobin increased 22.97 15.46 23 11228 11337 34934343
Toxic skin eruption 22.93 15.46 23 11228 11362 34934318
Hyperthermia 22.47 15.46 22 11229 10555 34935125
Haemoglobinuria 21.80 15.46 8 11243 607 34945073
Anaemia 21.24 15.46 138 11113 233197 34712483
Blood glucose increased 21.16 15.46 58 11193 66660 34879020
Hypomagnesaemia 20.58 15.46 30 11221 21821 34923859
Supraventricular extrasystoles 19.90 15.46 13 11238 3495 34942185
Anal incontinence 19.88 15.46 18 11233 7831 34937849
Haematoma 19.68 15.46 32 11219 25573 34920107
Glycosuria 19.47 15.46 9 11242 1228 34944452
Arteriovenous fistula site haematoma 19.39 15.46 4 11247 32 34945648
Thrombocytopenia 19.14 15.46 100 11151 156147 34789533
Interstitial lung disease 18.99 15.46 55 11196 65227 34880453
Extrasystoles 18.89 15.46 13 11238 3810 34941870
Off label use 18.57 15.46 71 11180 419453 34526227
Chronic kidney disease 18.57 15.46 41 11210 41169 34904511
Lung disorder 18.52 15.46 37 11214 34659 34911021
Renal tubular necrosis 18.49 15.46 24 11227 15656 34930024
Cardio-respiratory arrest 18.48 15.46 49 11202 55224 34890456
Blood glucose decreased 18.39 15.46 22 11229 13215 34932465
Prurigo 17.73 15.46 7 11244 648 34945032
Metabolic acidosis 16.98 15.46 41 11210 43639 34902041
Urine ketone body present 16.97 15.46 8 11243 1140 34944540
Hypocalcaemia 16.85 15.46 29 11222 24260 34921420
Gamma-glutamyltransferase increased 16.60 15.46 32 11219 29199 34916481
Vascular purpura 16.37 15.46 9 11242 1769 34943911
Pancreatitis acute 16.22 15.46 31 11220 28110 34917570
Blood lactic acid increased 16.20 15.46 15 11236 6713 34938967
Agranulocytosis 15.95 15.46 28 11223 23793 34921887
Medication error 15.78 15.46 29 11222 25536 34920144

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypoglycaemia 1247.02 14.18 569 18868 101025 79623926
Lactic acidosis 621.29 14.18 315 19122 70044 79654907
Acute kidney injury 444.03 14.18 586 18851 518818 79206133
Hypoglycaemic coma 365.00 14.18 104 19333 4656 79720295
Drug interaction 228.68 14.18 382 19055 414801 79310150
Hyperkalaemia 154.94 14.18 164 19273 114234 79610717
Pemphigoid 133.20 14.18 68 19369 15247 79709704
Diabetes mellitus inadequate control 104.08 14.18 68 19369 24196 79700755
Sopor 102.83 14.18 76 19361 32934 79692017
Hyperglycaemia 91.91 14.18 99 19338 70236 79654715
Hepatocellular injury 74.83 14.18 74 19363 47519 79677432
Anuria 71.50 14.18 51 19386 20912 79704039
Metabolic acidosis 66.60 14.18 91 19346 82438 79642513
Blood glucose increased 65.89 14.18 108 19329 114867 79610084
Cholestasis 65.71 14.18 72 19365 52037 79672914
Cardiac failure 62.63 14.18 125 19312 154717 79570234
Renal failure 61.58 14.18 145 19292 200823 79524128
Pancreatitis acute 58.18 14.18 66 19371 49538 79675413
Drug ineffective 54.55 14.18 114 19323 1080799 78644152
Anaemia 52.48 14.18 231 19206 444784 79280167
Bradyphrenia 48.53 14.18 31 19406 10609 79714342
Prothrombin consumption time prolonged 44.57 14.18 8 19429 38 79724913
Eosinophilia 44.36 14.18 55 19382 45290 79679661
Hypoglycaemic encephalopathy 44.24 14.18 13 19424 648 79724303
Oesophageal perforation 44.11 14.18 16 19421 1555 79723396
Rash maculo-papular 43.97 14.18 61 19376 56017 79668934
Transcription medication error 39.83 14.18 11 19426 438 79724513
Coronavirus infection 39.65 14.18 24 19413 7473 79717478
Product prescribing error 38.55 14.18 51 19386 44762 79680189
Arthralgia 37.30 14.18 51 19386 571752 79153199
Polymerase chain reaction 36.22 14.18 8 19429 123 79724828
Acute coronary syndrome 35.34 14.18 34 19403 21099 79703852
Confusional state 35.12 14.18 162 19275 317835 79407116
Joint swelling 33.83 14.18 14 19423 288632 79436319
Drug reaction with eosinophilia and systemic symptoms 33.65 14.18 58 19379 64186 79660765
Vascular purpura 33.62 14.18 16 19421 3082 79721869
Pain 33.10 14.18 77 19360 703725 79021226
Diabetic ketoacidosis 32.75 14.18 41 19396 34081 79690870
Fatigue 32.58 14.18 117 19320 929610 78795341
Off label use 32.57 14.18 113 19324 907102 78817849
Erythromelalgia 32.47 14.18 8 19429 202 79724749
Peripheral swelling 31.72 14.18 13 19424 269604 79455347
Hyperkinetic heart syndrome 30.40 14.18 7 19430 131 79724820
Glycosylated haemoglobin increased 30.36 14.18 30 19407 19230 79705721
Headache 30.35 14.18 72 19365 653700 79071251
Sinusitis 29.26 14.18 6 19431 195495 79529456
Chronic kidney disease 28.65 14.18 55 19382 66099 79658852
Pericardial haemorrhage 28.00 14.18 16 19421 4479 79720472
Dermatitis bullous 27.84 14.18 25 19412 14220 79710731
Dysarthria 27.80 14.18 55 19382 67567 79657384
Dehydration 27.80 14.18 127 19310 248060 79476891
Arthropathy 27.43 14.18 5 19432 177106 79547845
Infusion related reaction 27.25 14.18 11 19426 230226 79494725
Medication error 27.22 14.18 55 19382 68587 79656364
Completed suicide 27.10 14.18 13 19424 245754 79479197
Interstitial lung disease 26.90 14.18 74 19363 112526 79612425
Agranulocytosis 26.72 14.18 43 19394 44987 79679964
Toxic skin eruption 26.71 14.18 30 19407 22263 79702688
Rheumatoid arthritis 26.28 14.18 9 19428 208461 79516490
Loss of consciousness 25.99 14.18 95 19342 167848 79557103
Blood glucose decreased 25.94 14.18 32 19405 26202 79698749
Ischaemic stroke 25.91 14.18 36 19401 33095 79691856
Drug hypersensitivity 25.80 14.18 21 19416 298895 79426056
Shock haemorrhagic 25.77 14.18 28 19409 20032 79704919
Hypokinesia 25.18 14.18 27 19410 19033 79705918
Pancreatic carcinoma 24.91 14.18 23 19414 13554 79711397
Hypocalcaemia 24.75 14.18 44 19393 49880 79675071
Product prescribing issue 24.14 14.18 14 19423 4031 79720920
Pancreatitis 23.77 14.18 52 19385 68523 79656428
Hepatic cytolysis 23.50 14.18 31 19406 27120 79697831
Renal impairment 23.37 14.18 88 19349 157695 79567256
Maternal exposure during pregnancy 23.09 14.18 3 19434 136535 79588416
Hyperthermia 22.86 14.18 25 19412 18012 79706939
Haematoma 22.11 14.18 43 19394 52152 79672799
Haemoglobinuria 22.00 14.18 8 19429 783 79724168
Product dose omission issue 21.85 14.18 17 19420 247520 79477431
Euglycaemic diabetic ketoacidosis 21.85 14.18 16 19421 6828 79718123
Thrombocytopenia 20.85 14.18 123 19314 265136 79459815
Therapeutic product effect decreased 20.78 14.18 7 19430 163856 79561095
Nasopharyngitis 20.49 14.18 19 19418 253862 79471089
Poverty of speech 20.30 14.18 7 19430 587 79724364
Arteriovenous fistula site haematoma 20.28 14.18 4 19433 34 79724917
Ischaemic cardiomyopathy 20.18 14.18 16 19421 7679 79717272
Therapeutic product effect incomplete 19.89 14.18 5 19432 141640 79583311
Glycosuria 19.85 14.18 10 19427 2178 79722773
Supraventricular extrasystoles 19.34 14.18 15 19422 6972 79717979
Swelling 18.98 14.18 15 19422 216696 79508255
Hepatitis fulminant 18.83 14.18 15 19422 7247 79717704
Bradycardia 17.95 14.18 73 19364 135484 79589467
Hypomagnesaemia 17.90 14.18 37 19400 46874 79678077
Disorientation 17.80 14.18 44 19393 62732 79662219
Renal tubular necrosis 17.80 14.18 26 19411 25013 79699938
Septic shock 17.77 14.18 68 19369 122733 79602218
Prurigo 17.75 14.18 8 19429 1361 79723590
Drug intolerance 17.75 14.18 23 19414 264096 79460855
Death 17.41 14.18 75 19362 566439 79158512
Altered state of consciousness 17.24 14.18 35 19402 43787 79681164
Drug level increased 17.20 14.18 33 19404 39618 79685333
Blister 17.20 14.18 4 19433 119472 79605479
Resting tremor 16.95 14.18 8 19429 1513 79723438
Overdose 16.85 14.18 89 19348 184117 79540834
Dermatitis exfoliative generalised 16.76 14.18 14 19423 7227 79717724
Melaena 16.55 14.18 42 19395 60848 79664103
Lung disorder 16.39 14.18 50 19387 80507 79644444
Haematuria 16.20 14.18 45 19392 68791 79656160
Anal incontinence 16.12 14.18 21 19416 18147 79706804
Atrioventricular block complete 16.00 14.18 20 19417 16590 79708361
Fall 15.82 14.18 185 19252 487444 79237507
Asthenia 15.67 14.18 192 19245 511497 79213454
Cardio-respiratory arrest 15.63 14.18 60 19377 108450 79616501
Hypoglycaemic unconsciousness 15.62 14.18 7 19430 1176 79723775
Subacute cutaneous lupus erythematosus 15.31 14.18 10 19427 3551 79721400
Infection 15.28 14.18 22 19415 241690 79483261
Somnambulism 15.23 14.18 12 19425 5709 79719242
Acute pulmonary oedema 15.11 14.18 18 19419 14212 79710739
Wheezing 14.76 14.18 5 19432 116659 79608292
Product use in unapproved indication 14.66 14.18 24 19413 250335 79474616
Extrasystoles 14.46 14.18 13 19424 7406 79717545
Arthritis 14.40 14.18 5 19432 114875 79610076
Gingival abscess 14.39 14.18 6 19431 846 79724105
Anxiety 14.39 14.18 24 19413 248488 79476463
Flatulence 14.35 14.18 32 19405 42692 79682259
Hypotension 14.25 14.18 167 19270 440150 79284801
Muscle haemorrhage 14.21 14.18 12 19425 6288 79718663

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A10BD14 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BX02 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Other blood glucose lowering drugs, excl. insulins
FDA EPC N0000175428 Glinide
FDA MoA N0000175448 Potassium Channel Antagonists
MeSH PA D007004 Hypoglycemic Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Diabetes mellitus type 2 indication 44054006 DOID:9352
Alcoholism contraindication 7200002
Asthenia contraindication 13791008
Myocardial infarction contraindication 22298006 DOID:5844
Acute vomiting contraindication 23971007
Severe adrenal insufficiency contraindication 24867002
Alcohol intoxication contraindication 25702006
Shock contraindication 27942005
Dehydration contraindication 34095006
Infectious disease contraindication 40733004
Ketoacidosis contraindication 56051008
Acute nephropathy contraindication 58574008
Metabolic acidosis contraindication 59455009
Acute infectious disease contraindication 63171007
Hypopituitarism contraindication 74728003 DOID:9406
Cardiogenic shock contraindication 89138009
Kidney disease contraindication 90708001 DOID:557
Lactic acidosis contraindication 91273001 DOID:3650
Cobalamin deficiency contraindication 190634004
Decompensated cardiac failure contraindication 195111005
Disease of liver contraindication 235856003 DOID:409
Hypoglycemic disorder contraindication 237630007
Sepsis syndrome contraindication 238150007
Primary adrenocortical insufficiency contraindication 373662000
Adrenal cortical hypofunction contraindication 386584007 DOID:10493
Fever contraindication 386661006
Surgical procedure contraindication 387713003
Severe diarrhea contraindication 409587002
Breastfeeding (mother) contraindication 413712001
Traumatic injury contraindication 417746004
Radiography with IV Iodinated Contrast Agent contraindication
Severe Hypoxemia contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.43 acidic
pKa2 3.8 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Sulfonylurea receptor 1, Kir6.2 Ion channel BLOCKER Ki 9.14 WOMBAT-PK CHEMBL
ATP-binding cassette sub-family C member 8 Ion channel Kd 7.30 CHEMBL
Solute carrier organic anion transporter family member 1B1 Transporter WOMBAT-PK
Solute carrier family 22 member 1 Transporter IC50 5.04 CHEMBL
Sulfonylurea receptor 2, Kir6.2 Ion channel BLOCKER Ki 8.81 WOMBAT-PK

External reference:

IDSource
4021119 VUID
N0000148573 NUI
D00594 KEGG_DRUG
4021119 VANDF
C0246689 UMLSCUI
CHEBI:8805 CHEBI
BJX PDB_CHEM_ID
CHEMBL1272 ChEMBL_ID
DB00912 DRUGBANK_ID
C072379 MESH_SUPPLEMENTAL_RECORD_UI
6841 IUPHAR_LIGAND_ID
6818 INN_ID
668Z8C33LU UNII
65981 PUBCHEM_CID
219335 RXNORM
11576 MMSL
120643 MMSL
5416 MMSL
d04267 MMSL
007421 NDDF
109074004 SNOMEDCT_US
386964000 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Repaglinide HUMAN PRESCRIPTION DRUG LABEL 1 0574-0240 TABLET 0.50 mg ORAL ANDA 25 sections
Repaglinide HUMAN PRESCRIPTION DRUG LABEL 1 0574-0240 TABLET 0.50 mg ORAL ANDA 25 sections
Repaglinide HUMAN PRESCRIPTION DRUG LABEL 1 0574-0241 TABLET 1 mg ORAL ANDA 25 sections
Repaglinide HUMAN PRESCRIPTION DRUG LABEL 1 0574-0241 TABLET 1 mg ORAL ANDA 25 sections
Repaglinide HUMAN PRESCRIPTION DRUG LABEL 1 0574-0242 TABLET 2 mg ORAL ANDA 25 sections
Repaglinide HUMAN PRESCRIPTION DRUG LABEL 1 0574-0242 TABLET 2 mg ORAL ANDA 25 sections
Repaglinide Human Prescription Drug Label 1 33342-248 TABLET 0.50 mg ORAL ANDA 25 sections
Repaglinide Human Prescription Drug Label 1 33342-249 TABLET 1 mg ORAL ANDA 25 sections
Repaglinide Human Prescription Drug Label 1 33342-250 TABLET 2 mg ORAL ANDA 25 sections
REPAGLINIDE HUMAN PRESCRIPTION DRUG LABEL 1 51991-853 TABLET 0.50 mg ORAL ANDA 24 sections
REPAGLINIDE HUMAN PRESCRIPTION DRUG LABEL 1 51991-854 TABLET 1 mg ORAL ANDA 24 sections
REPAGLINIDE HUMAN PRESCRIPTION DRUG LABEL 1 51991-855 TABLET 2 mg ORAL ANDA 24 sections
Prandin HUMAN PRESCRIPTION DRUG LABEL 1 54868-5381 TABLET 2 mg ORAL NDA 21 sections
Prandin HUMAN PRESCRIPTION DRUG LABEL 1 54868-6439 TABLET 1 mg ORAL NDA 21 sections
Repaglinide Human Prescription Drug Label 1 57237-157 TABLET 0.50 mg ORAL ANDA 25 sections
Repaglinide Human Prescription Drug Label 1 57237-158 TABLET 1 mg ORAL ANDA 25 sections
Repaglinide Human Prescription Drug Label 1 57237-159 TABLET 2 mg ORAL ANDA 25 sections
Repaglinide HUMAN PRESCRIPTION DRUG LABEL 1 57664-745 TABLET 1 mg ORAL ANDA 25 sections
Repaglinide HUMAN PRESCRIPTION DRUG LABEL 1 57664-747 TABLET 2 mg ORAL ANDA 25 sections
REPAGLINIDE HUMAN PRESCRIPTION DRUG LABEL 1 60429-484 TABLET 0.50 mg ORAL ANDA 24 sections
REPAGLINIDE HUMAN PRESCRIPTION DRUG LABEL 1 60429-485 TABLET 1 mg ORAL ANDA 24 sections
REPAGLINIDE HUMAN PRESCRIPTION DRUG LABEL 1 60429-486 TABLET 2 mg ORAL ANDA 24 sections
Repaglinide HUMAN PRESCRIPTION DRUG LABEL 1 60687-560 TABLET 1 mg ORAL ANDA 25 sections
Repaglinide HUMAN PRESCRIPTION DRUG LABEL 1 60687-560 TABLET 1 mg ORAL ANDA 25 sections
Prandin HUMAN PRESCRIPTION DRUG LABEL 1 60846-882 TABLET 1 mg ORAL ANDA 28 sections
Prandin HUMAN PRESCRIPTION DRUG LABEL 1 60846-884 TABLET 2 mg ORAL ANDA 28 sections
Repaglinide HUMAN PRESCRIPTION DRUG LABEL 1 63629-8363 TABLET 2 mg ORAL ANDA 25 sections
Repaglinide HUMAN PRESCRIPTION DRUG LABEL 1 63629-8363 TABLET 2 mg ORAL ANDA 25 sections
Repaglinide HUMAN PRESCRIPTION DRUG LABEL 1 63629-8447 TABLET 0.50 mg ORAL ANDA 25 sections
Repaglinide HUMAN PRESCRIPTION DRUG LABEL 1 63629-8447 TABLET 0.50 mg ORAL ANDA 25 sections